Charu Aggarwal, MD, MPH

Before closing out their discussion on non–small cell lung cancer, experts share excitement for possible improvements in the setting of perioperative therapy.

Experts consider when and if it would be appropriate to utilize targeted or immunotherapy in patients with EGFR exon 19 deletion–positive NSCLC.

Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.

A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.

Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.

Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.

A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.

Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.

Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.

Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.

“In my mind, the question is not who should get chemotherapy, but who can avoid chemotherapy in this day and age.”